Impulsive and compulsive behaviors in parkinson's disease

Annual Review of Clinical Psychology

Volumn 10, Issue , 2014, Pages 553-580

  Averbeck, B B ^a   O'Sullivan, S S ^b   Djamshidian, A ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine agonists; Impulsive compulsive behaviors; Neuropsychiatry; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ADDICTION; ALCOHOL ABUSE; ALEXITHYMIA; ANXIETY DISORDER; BEHAVIOR DISORDER; CLINICAL FEATURE; COMPULSIVE SHOPPING; COPING BEHAVIOR; DEPRESSION; DOPAMINE DYSREGULATION SYNDROME; DRUG RECEPTOR BINDING; DYSKINESIA; GAIT DISORDER; HEREDITY; HUMAN; IMPULSIVE AND COMPULSIVE BEHAVIOR; IMPULSIVENESS; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NEUROSIS; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERSONALITY; PHENOMENOLOGY; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSEXUAL DISORDER; PUNDING; REVIEW; RISK FACTOR; SUBSTITUTION THERAPY; TREMOR;

COMPULSIVE BEHAVIOR; HUMANS; IMPULSIVE BEHAVIOR; PARKINSON DISEASE; RISK FACTORS;

EID: 84897380489     PISSN: 15485943     EISSN: 15485951     Source Type: Book Series    
DOI: 10.1146/annurev-clinpsy-032813-153705     Document Type: Review

References (168)

1. Ahlskog JE. 2011. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol. Behav. 104:168-72
2. Am. Psychiatr. Assoc. 2013. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Publ. 5th e.d.
3. Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, et al. 2011. Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov. Disord. 26:464-68
4. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, et al. 2006. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov. Disord. 21:1941-46
5. Averbeck BB, Djamshidian A, O'Sullivan SS, Housden CR, Roiser JP, Lees AJ. 2013. Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: Evidence from Parkinson's disease. Behav. Neurosci. 127:245-55
6. Avila A, Cardona X, Bello J, Maho P, Sastre F, Martin-Baranera M. 2011. Impulse control disorders and punding in Parkinson's disease: The need for a structured interview. Neurologia 26:166-72
7. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. 2013. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov. Disord. 28:327-33
8. Bechara A, Damasio AR, Damasio H, Anderson SW. 1994. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50:7-15
9. Bermejo PE. 2008. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 14:448-49
10. Bermejo PE, Ruiz-Huete C, Anciones B. 2010. Zonisamide in managing impulse control disorders in Parkinson's disease. J. Neurol. 257:1682-85
11. Berridge KC. 2007. The debate over dopamine's role in reward: The case for incentive salience. Psychopharmacology (Berl.) 191:391-431
12. Bienfait KL, Menza M, Mark MH, Dobkin RD. 2010. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. J. Clin. Neurosci. 17:539-40
13. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. 2002. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann. Clin. Psychiatry 14:9-15
14. Bodi N, Keri S, Nagy H, Moustafa A, Myers CE, et al. 2009. Reward-learning and the novelty-seeking personality: A between-And within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 132:2385-95
15. BortolatoM, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. 2012. Finasteride attenuates pathological gambling in patients with Parkinson disease. J. Clin. Psychopharmacol. 32:424-25
16. BoscoD, Plastino M, Colica C, Bosco F, Arianna S, et al. 2012. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin. Neuropharmacol. 35:118-20
17. Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. 2011. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: A review. Parkinsonism Relat. Disord. 17:413-17
18. Canesi M, Rusconi ML, Isaias IU, Pezzoli G. 2012. Artistic productivity and creative thinking in Parkinson's disease. Eur. J. Neurol. 19:468-72
19. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. 2005. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735-40
20. Cheng HC, Ulane CM, Burke RE. 2010. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67:715-25
21. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, et al. 2008. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol. 65:1604-11
22. Clark L, Robbins TW, Ersche KD, Sahakian BJ. 2006. Reflection impulsivity in current and former substance users. Biol. Psychiatry 60:515-22
23. Cools R, Barker RA, Sahakian BJ, Robbins TW. 2001. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 11:1136-43
24. Cormier F, Muellner J, Corvol JC. 2013. Genetics of impulse control disorders in Parkinson's disease. J. Neural Transm. 120:665-71
25. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. 2010. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: A case-control study. Sleep 33:81-87
26. Dagher A, Robbins TW. 2009. Personality, addiction, dopamine: Insights from Parkinson's disease. Neuron 61:502-10
27. Dalley JW, Everitt BJ, Robbins TW. 2011. Impulsivity, compulsivity, and top-down cognitive control. Neuron 69:680-94
28. Dalley JW, Roiser JP. 2012. Dopamine, serotonin and impulsivity. Neuroscience 215:42-58
29. de Lau LM, Breteler MM. 2006. Epidemiology of Parkinson's disease. Lancet Neurol. 5:525-35
30. Delaney M, Leroi I, Simpson J, Overton PG. 2012. Impulse control disorders in Parkinson's disease: A psychosocial perspective. J. Clin. Psychol. Med. Settings 19:338-46
31. Dickman SJ. 1990. Functional and dysfunctional impulsivity: Personality and cognitive correlates. J. Personal. Soc. Psychol. 58:95-102
32. Djamshidian A, Averbeck BB, Lees AJ, O'Sullivan SS. 2011a. Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. J. Neurol. Sci. 310:183-88
33. Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ. 2011b. Pathological gambling in Parkinson's disease-A review of the literature. Mov. Disord. 26:1976-84
34. Djamshidian A, Jha A, O'Sullivan SS, Silveira-Moriyama L, Jacobson C, et al. 2010. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov. Disord. 25:2203-10
35. Djamshidian A, O'Sullivan SS, Doherty K, Lees AJ, Averbeck BB. 2011c. Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. Neuropsychologia 49:103-7
36. Djamshidian A, O'Sullivan SS, Foltynie T, Aviles-Olmos I, Limousin P, et al. 2013. Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson's disease. J. Parkinson'sDis. 3:139-44
37. Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. 2011d. Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism Relat. Disord. 17:212-14
38. Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. 2012a. Effects of dopamine on sensitivity to social bias in Parkinson's disease. PLoS ONE 7:e32889
39. Djamshidian A, O'Sullivan SS, Papadopoulos A, Bassett P, Shaw K, et al. 2011e. Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J. Neurol. Neurosurg. Psychiatry 82:1107-11
40. Djamshidian A, O'Sullivan SS, Sanotsky Y, Sharman S, Matviyenko Y, et al. 2012b. Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions? Mov. Disord. 27:1137-45
41. Djamshidian A, O'Sullivan SS, Wittmann BC, Lees AJ, Averbeck BB. 2011f. Novelty seeking behaviour in Parkinson's disease. Neuropsychologia 49:2483-8
42. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, et al. 2004. Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Mov. Disord. 19:397-405
43. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. 2005. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65:1570-74
44. Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R, et al. 2006a. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 77:317-21
45. Evans AH, Lees AJ. 2004. Dopamine dysregulation syndrome in Parkinson's disease. Curr. Opin. Neurol. 17:393-98
46. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, et al. 2006b. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 59:852-58
47. Evans AH, Strafella AP, Weintraub D, Stacy M. 2009. Impulsive and compulsive behaviors in Parkinson's disease. Mov. Disord. 24:1561-70
48. Evenden JL. 1999. Varieties of impulsivity. Psychopharmacology (Berl.) 146:348-61
49. Fan W, Ding H, Ma J, Chan P. 2009. Impulse control disorders in Parkinson's disease in a Chinese population. Neurosci. Lett. 465:6-9
50. Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. 2011. Management of punding in Parkinson's disease: An open-label prospective study. J. Neurol. 258:656-60
51. Franco C, Paris JJ, Wulfert E, Frye CA. 2009. Male gamblers have significantly greater salivary cortisol before and after betting on a horse race, than do female gamblers. Physiol. Behav. 99:225-29
52. FrankMJ, Samanta J, Moustafa AA, Sherman SJ. 2007. Hold your horses: Impulsivity, deep brain stimulation, and medication in parkinsonism. Science 318:1309-12
53. Frank MJ, Seeberger LC, O'Reilly R C. 2004. By carrot or by stick: Cognitive reinforcement learning in parkinsonism. Science 306:1940-3
54. Friedman JH. 1994. Punding on levodopa. Biol. Psychiatry 36:350-51
55. Friedman JH, Chang V. 2013. Crack cocaine use due to dopamine agonist therapy in Parkinson disease. Neurology 80:2269-70
56. Frosini D, Pesaresi I, Cosottini M, Belmonte G, Rossi C, et al. 2010. Parkinson's disease and pathological gambling: Results from a functional MRI study. Mov. Disord. 25:2449-53
57. Furl N, Averbeck BB. 2011. Parietal cortex and insula relate to evidence seeking relevant to reward-related decisions. J. Neurosci. 31:17572-82
58. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. 2007. Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov. Disord. 22:1757-63
59. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. 2003. Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm. 110:1119-27
60. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. 2000. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psychiatry 68:423-28
61. Goeders NE. 2002. Stress and cocaine addiction. J. Pharmacol. Exp. Ther. 301:785-89
62. Gotham AM, Brown RG, Marsden CD. 1988. Frontal cognitive function in patients with Parkinson's disease on and off levodopa. Brain 111(Part 2):299-321
63. Grant JE, Chamberlain SR, Odlaug BL, PotenzaMN, Kim SW. 2010. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: A pilot study. Psychopharmacology (Berl.) 212:603-12
64. Grant JE, Odlaug BL, Kim SW. 2009. N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Arch. Gen. Psychiatry 66:756-63
65. Gurevich EV, Joyce JN. 1999. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60-80
66. Halbig TD, Tse W, Frisina PG, Baker BR, Hollander E, et al. 2009. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur. J. Neurol. 16:493-97
67. Hardman CD, Henderson JM, Finkelstein DI, Horne MK, Paxinos G, Halliday GM. 2002. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: Volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J. Comp. Neurol. 445:238-55
68. Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, et al. 2011. Dopamine agonist-Triggered pathological behaviors: Surveillance in the PDclinic reveals high frequencies. Parkinsonism Relat. Disord. 17:260-64
69. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R 2007. How common are the common neurologic disorders? Neurology 68:326-37
70. Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M, et al. 2010. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch. Gen. Psychiatry 67:946-54
71. Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP. 2010. Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 35:2155-64
72. Joutsa J, Martikainen K, Niemela S, Johansson J, Forsback S, et al. 2012a. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov. Disord. 27:778-82
73. Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. 2012b. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 18:1079-83
74. Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. 2012c. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat. Disord. 18:155-60
75. Kagan J. 1966. Reflection-impulsivity: The generality and dynamics of conceptual tempo. J. Abnorm. Psychol. 71:17-24
76. Kalivas PW. 2009. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10:561-72
77. Kirby KN, Petry NM, Bickel WK. 1999. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J. Exp. Psychol. Gen. 128:78-87
78. Kish SJ, Shannak K, Hornykiewicz O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318:876-80
79. Koob GF, Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35:217-38
80. Langer EJ. 1975. The illusion of control. J. Personal. Soc. Psychol. 32:311-28
81. Lee JY, Jeon BS, Kim HJ, Park SS. 2012. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat. Disord. 18:76-78
82. Lee JY, Kim HJ, Jeon BS. 2011. Is pathological gambling in Parkinson's disease reduced by amantadine? Ann. Neurol. 69:213-14; author reply 214-15
83. Lee JY, Kim JM, Kim JW, Cho J, Lee WY, et al. 2009. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat. Disord. 16:202-7
84. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373:2055-66
85. Leroi I, Ahearn DJ, Andrews M, McDonald KR, Byrne EJ, Burns A. 2011. Behavioural disorders, disability and quality of life in Parkinson's disease. Age Ageing 40:614-21
86. Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. 2012. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int. J. Geriatr. Psychiatry 27:160-66
87. Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C, et al. 2012. Subthalamic stimulation in Parkinson's disease: Restoring the balance of motivated behaviours. Brain 135:1463-77
88. Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C, et al. 2009. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J. Clin. Neurosci. 16:1148-52
89. Lovallo WR. 2006. Cortisol secretion patterns in addiction and addiction risk. Int. J. Psychophysiol. 59:195-202
90. Lu C, Bharmal A, Suchowersky O. 2006. Gambling and Parkinson disease. Arch. Neurol. 63:298
91. Macphee GJ, Copeland C, Stewart D, Grosset K, Grosset DG. 2009. Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov. Disord. 24:2430-31
92. Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, et al. 2008. Long-Term follow-up of impulse control disorders in Parkinson's disease. Mov. Disord. 23:75-80
93. McElroy SL, Keck PE Jr, Pope HG Jr, Smith JM, Strakowski SM. 1994. Compulsive buying: A report of 20 cases. J. Clin. Psychiatry 55:242-48
94. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. 2008. Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial. J. Clin. Psychiatry 69:433-40
95. McKeon A, Josephs KA, Klos KJ, Hecksel K, Bower JH, et al. 2007. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat. Disord. 13:516-19
96. Menza M. 2000. The personality associated with Parkinson's disease. Curr. Psychiatry Rep. 2:421-26
97. Menza MA, Golbe LI, Cody RA, Forman NE. 1993. Dopamine-related personality traits in Parkinson's disease. Neurology 43:505-8
98. Mestre T, Strafella AP, Thomsen T, Voon V, Miyasaki J. 2013. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther. Adv. Neurol. Disord. 6:175-88
99. Meyer G, Hauffa BP, Schedlowski M, Pawlak C, Stadler MA, Exton MS. 2000. Casino gambling increases heart rate and salivary cortisol in regular gamblers. Biol. Psychiatry 48:948-53
100. Milenkova M, Mohammadi B, Kollewe K, Schrader C, Fellbrich A, et al. 2011. Intertemporal choice in Parkinson's disease. Mov. Disord. 26:2004-10
101. MoumSJ, Price CC, Limotai N, Oyama G, Ward H, et al. 2012. Effects of STNandGPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS ONE 7:e29768
102. Muresanu DF, Stan A, Buzoianu A. 2012. Neuroplasticity and impulse control disorders. J. Neurol. Sci. 316:15-20
103. O'Sullivan SS, Djamshidian A, Ahmed Z, Evans AH, Lawrence AD, et al. 2010a. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov. Disord. 25:638-42
104. O'Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD. 2010b. Excessive hoarding in Parkinson's disease. Mov. Disord. 25:1026-33
105. O'Sullivan SS, Evans AH, Lees AJ. 2007. Punding in Parkinson's disease. Pract. Neurol. 7:397-99
106. O'Sullivan SS, Evans AH, Lees AJ. 2009. Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs 23:157-70
107. O'Sullivan SS, Evans AH, Quinn NP, Lawrence AD, Lees AJ. 2010c. Reckless generosity in Parkinson's disease. Mov. Disord. 25:221-23
108. O'Sullivan SS, Loane CM, Lawrence AD, Evans AH, Piccini P, Lees AJ. 2010d. Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 82:620-22
109. O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, et al. 2011. Cue-induced striatal dopamine release in Parkinson's disease-Associated impulsive-compulsive behaviours. Brain 134:969-78
110. Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, et al. 2013. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80:792-99
111. Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, et al. 2011. Patient versus informant reporting of ICD symptoms in Parkinson's disease using theQUIP: Validity and variability. Parkinsonism Relat. Disord. 17:153-55
112. Parkinson J. 1817. An Essay on the Shaking Palsy. London: Sherwood, Neely, Jones
113. Patton JH, Stanford MS, Barratt ES. 1995. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 51:768-74
114. PetryNM, Stinson FS, Grant BF. 2005. Comorbidity ofDSM-IV pathological gambling and other psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 66:564-74
115. Poletti M, Bonuccelli U. 2012. Personality traits in patients with Parkinson's disease: Assessment and clinical implications. J. Neurol. 259:1029-38
116. Poletti M, Frosini D, Pagni C, Claudio L, Paolo delD, et al. 2012. Alexithymia is associated with impulsivity in newly-diagnosed, drug-naive patientswith Parkinson's disease: An affective risk factor for the development of impulse-control disorders? J. Neuropsychiatry Clin. Neurosci. 24:E36-37
117. Politis M, Loane C, Wu K, O'Sullivan SS, Woodhead Z, et al. 2013. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain 136:400-11
118. Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, et al. 2013. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J. Neurol. Neurosurg. Psychiatry 84:130-35
119. RabinakCA, Nirenberg MJ. 2010. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch.Neurol. 67:58-63
120. RainaG, Cersosimo MG, Micheli F. 2012. Zoophilia and impulse control disorder in a patient with Parkinson disease. J. Neurol. 259:969-70
121. RayNJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, et al. 2012. Extrastriatal dopaminergic abnormalities ofDA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. Neurobiol. Dis. 48:519-25
122. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, et al. 2012. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229-36
123. Rizos A, Martinez-Martin P, Martin A, Henriksen T, Kessel B, et al. 2012. European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD. Mov. Disord. 27(Suppl. 1):161 (Abstr
124. Robbins TW, Gillan CM, Smith DG, de Wit S, Ersche KD. 2012. Neurocognitive endophenotypes of impulsivity and compulsivity: Towards dimensional psychiatry. Trends Cogn. Sci. 16:81-91
125. Robinson TE, Berridge KC. 2008. Review. The incentive sensitization theory of addiction: Some current issues. Philos. Trans. R. Soc. B 363:3137-46
126. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, Alegre M, Toledo J, et al. 2010. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 134:36-49
127. Rogers RD, Wielenberg B, Wojtecki L, Elben S, Campbell-Meiklejohn D, Schnitzler A. 2011. Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson's disease. Exp. Neurol. 231:181-89
128. Rossi M, Gerschcovich ER, de Achaval D, Perez-Lloret S, Cerquetti D, et al. 2010. Decision-making in Parkinson's disease patients with and without pathological gambling. Eur. J. Neurol. 17:97-102
129. Rylander G. 1972. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr. Neurol. Neurochir. 75:203-12
130. Saint-Cyr JA, Hoque T, Pereira LC, Dostrovsky JO, Hutchison WD, et al. 2002. Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J. Neurosurg. 97:1152-66
131. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. 2009. The in vitro receptor profile of rotigotine: A new agent for the treatment of Parkinson's disease. Naunyn Schmeidebergs Arch. Pharmacol. 379:73-86
132. Schwingenschuh P, Katschnig P, Saurugg R, Ott E, Bhatia KP. 2010. Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? Mov. Disord. 25:493-96
133. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, et al. 2011. The Movement Disorder Society Evidence-Based MedicineReview update: Treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26(Suppl. 3):S42-80
134. Sevincok L, Akoglu A, Akyol A. 2007. Quetiapine in a case with Parkinson disease and pathological gambling. J. Clin. Psychopharmacol. 27:107-8
135. Sgambato-Faure V, Cenci MA. 2012. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. 96:69-86
136. Shiner T, Seymour B, Wunderlich K, Hill C, Bhatia KP, et al. 2012. Dopamine and performance in a reinforcement learning task: Evidence from Parkinson's disease. Brain 135:1871-83
137. Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. 2006. Punding and dyskinesias. Mov. Disord. 21:2214-17
138. Singh A, Kandimala G, Dewey RB Jr, O'Suilleabhain P. 2007. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J. Clin. Neurosci. 14:1178-81
139. Siri C, Cilia R, De Gaspari D, Canesi M, Meucci N, et al. 2010. Cognitive status of patients with Parkinson's disease and pathological gambling. J. Neurol. 257:247-52
140. SohtaogluM, Demiray DY, Kenangil G, Ozekmekci S, Erginoz E. 2010. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat. Disord. 16:334-37
141. Sokoloff P, Giros B, Martres MP, BouthenetML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-51
142. Solla P, Cannas A, Marrosu MG, Marrosu F. 2012. Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. J. Neurol. 259:2752-54
143. Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, et al. 2013. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J. Neurol. 260:521-27
144. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, et al. 2009. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: A [11C] raclopride PET study. Brain 132:1376-85
145. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. 2010. Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol. 68:400-4
146. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. 2012. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat. Disord. 18:397-99
147. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP 2009. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: A trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 34:2758-66
148. Verdejo-Garcia A, Lawrence AJ, Clark L. 2008. Impulsivity as a vulnerability marker for substance-use disorders: Review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci. Biobehav. Rev. 32:777-810
149. Vitale C, Santangelo G, Erro R, Errico D, Manganelli F, et al. 2013. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: Report of 2 cases. Parkinsonism Relat. Disord. 19:483-84
150. Vlaar A, Hovestadt A, van Laar T, Bloem BR. 2011. The treatment of early Parkinson's disease: Levodopa rehabilitated. Pract. Neurol. 11:145-52
151. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, et al. 1997. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-30
152. Volkow ND, Wang GJ, Fowler JS, Telang F. 2008. Overlapping neuronal circuits in addiction and obesity: Evidence of systems pathology. Philos. Trans. R. Soc. B 363:3191-200
153. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, et al. 2009. Chronic dopaminergic stimulation in Parkinson's disease: From dyskinesias to impulse control disorders. Lancet Neurol. 8:1140-49
154. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, et al. 2006. Prevalence of repetitive and rewardseeking behaviors in Parkinson disease. Neurology 67:1254-57
155. Voon V, Mehta AR, Hallett M. 2011a. Impulse control disorders in Parkinson's disease: Recent advances. Curr. Opin. Neurol. 24:324-30
156. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, et al. 2010a.Mechanisms underlying dopaminemediated reward bias in compulsive behaviors. Neuron 65:135-42
157. Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, et al. 2010b. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl.) 207:645-59
158. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, et al. 2011b. Impulse control disorders in Parkinson disease: A multicenter case-control study. Ann. Neurol. 69:986-96
159. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, et al. 2007. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch. Neurol. 64:212-16
160. Weintraub D, Hoops S, Shea JA, LyonsKE, PahwaR, et al. 2009. Validation of the questionnaire for impulsivecompulsive disorders in Parkinson's disease. Mov. Disord. 24:1461-67
161. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, et al. 2010a. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch. Neurol. 67:589-95
162. Weintraub D, Papay K, Siderowf A. 2013. Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study. Neurology 80:176-80
163. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, et al. 2010b. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann. Neurol. 68:963-68
164. Willis AW, SchootmanM, Kung N, Racette BA. 2013. Epidemiology and neuropsychiatric manifestations of young onset Parkinson's disease in the United States. Parkinsonism Relat. Disord. 19:202-6
165. Wittmann BC, Daw ND, Seymour B, Dolan RJ. 2008. Striatal activity underlies novelty-based choice in humans. Neuron 58:967-73
166. Wylie SA, Claassen DO, HuizengaHM, Schewel KD, Ridderinkhof KR, et al. 2012a. Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. J. Cogn. Neurosci. 24:1709-24
167. Wylie SA, van denWildenberg W, Ridderinkhof KR, Claassen DO, Wooten GF, Manning CA. 2012b. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 83:1149-54
168. Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CE 4th, et al. 2011. Binge eating in Parkinson's disease: Prevalence, correlates and the contribution of deep brain stimulation. J. Neuropsychiatry Clin. Neurosci. 23:56-62.